Search

Your search keyword '"Farci, Patrizia"' showing total 445 results
Start Over Author "Farci, Patrizia"
445 results on '"Farci, Patrizia"'

1. Anti-PF4 antibodies associated with disease severity in COVID-19

Author

Liu, Qingbo, Miao, Huiyi, Li, Shuai, Zhang, Peng, Gerber, Gloria F., Follmann, Dean, Ji, Hongkai, Zeger, Scott L., Chertow, Daniel S., Quinn, Thomas C., Robinson, Matthew L., Kickler, Thomas S., Rothman, Richard E., Fenstermacher, Katherine Z. J., Braunstein, Evan M., Cox, Andrea L., Farci, Patrizia, Fauci, Anthony S., and Lusso, Paolo

Published
2022

3. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Author

Kramvis, Anna, Chang, Kyong-Mi, Dandri, Maura, Farci, Patrizia, Glebe, Dieter, Hu, Jianming, Janssen, Harry L. A., Lau, Daryl T. Y., Penicaud, Capucine, Pollicino, Teresa, Testoni, Barbara, Van Bömmel, Florian, Andrisani, Ourania, Beumont-Mauviel, Maria, Block, Timothy M., Chan, Henry L. Y., Cloherty, Gavin A., Delaney, William E., Geretti, Anna Maria, Gehring, Adam, Jackson, Kathy, Lenz, Oliver, Maini, Mala K., Miller, Veronica, Protzer, Ulrike, Yang, Jenny C., Yuen, Man-Fung, Zoulim, Fabien, and Revill, Peter A.

Published
2022
Full Text
View/download PDF

4. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants

Author

Chen, Zhaochun, Zhang, Peng, Matsuoka, Yumiko, Tsybovsky, Yaroslav, West, Kamille, Santos, Celia, Boyd, Lisa F., Nguyen, Hanh, Pomerenke, Anna, Stephens, Tyler, Olia, Adam S., Zhang, Baoshan, De Giorgi, Valeria, Holbrook, Michael R., Gross, Robin, Postnikova, Elena, Garza, Nicole L., Johnson, Reed F., Margulies, David H., Kwong, Peter D., Alter, Harvey J., Buchholz, Ursula J., Lusso, Paolo, and Farci, Patrizia

Published
2022
Full Text
View/download PDF

6. Fibrosis and Hepatocarcinogenesis: Role of Gene-Environment Interactions in Liver Disease Progression.

Author

Banerjee, Anindita and Farci, Patrizia

Subjects
*HEPATIC fibrosis, *LIVER cells, *TREATMENT effectiveness, *GENOTYPE-environment interaction, *CIRRHOSIS of the liver
Abstract

The liver is a complex organ that performs vital functions in the body. Despite its extraordinary regenerative capacity compared to other organs, exposure to chemical, infectious, metabolic and immunologic insults and toxins renders the liver vulnerable to inflammation, degeneration and fibrosis. Abnormal wound healing response mediated by aberrant signaling pathways causes chronic activation of hepatic stellate cells (HSCs) and excessive accumulation of extracellular matrix (ECM), leading to hepatic fibrosis and cirrhosis. Fibrosis plays a key role in liver carcinogenesis. Once thought to be irreversible, recent clinical studies show that hepatic fibrosis can be reversed, even in the advanced stage. Experimental evidence shows that removal of the insult or injury can inactivate HSCs and reduce the inflammatory response, eventually leading to activation of fibrolysis and degradation of ECM. Thus, it is critical to understand the role of gene-environment interactions in the context of liver fibrosis progression and regression in order to identify specific therapeutic targets for optimized treatment to induce fibrosis regression, prevent HCC development and, ultimately, improve the clinical outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection.

Author

Raghwani, Jayna, Rose, Rebecca, Sheridan, Isabelle, Lemey, Philippe, Suchard, Marc A, Santantonio, Teresa, Farci, Patrizia, Klenerman, Paul, and Pybus, Oliver G

Subjects
Humans, Hepacivirus, HIV-1, Hepatitis C, Chronic, HIV Infections, Follow-Up Studies, Evolution, Molecular, Virus Replication, Female, Male, Evolution, Molecular, Hepatitis C, Chronic, Virology, Microbiology, Immunology, Medical Microbiology
Abstract

The treatment of HCV infection has seen significant progress, particularly since the approval of new direct-acting antiviral drugs. However these clinical achievements have been made despite an incomplete understanding of HCV replication and within-host evolution, especially compared with HIV-1. Here, we undertake a comprehensive analysis of HCV within-host evolution during chronic infection by investigating over 4000 viral sequences sampled longitudinally from 15 HCV-infected patients. We compare our HCV results to those from a well-studied HIV-1 cohort, revealing key differences in the evolutionary behaviour of these two chronic-infecting pathogens. Notably, we find an exceptional level of heterogeneity in the molecular evolution of HCV, both within and among infected individuals. Furthermore, these patterns are associated with the long-term maintenance of viral lineages within patients, which fluctuate in relative frequency in peripheral blood. Together, our findings demonstrate that HCV replication behavior is complex and likely comprises multiple viral subpopulations with distinct evolutionary dynamics. The presence of a structured viral population can explain apparent paradoxes in chronic HCV infection, such as rapid fluctuations in viral diversity and the reappearance of viral strains years after their initial detection.

Published
2016

11. Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway

Author

Chen, Jian, Zaidi, Sobia, Rao, Shuyun, Chen, Jiun-Sheng, Phan, Liem, Farci, Patrizia, Su, Xiaoping, Shetty, Kirti, White, Jon, Zamboni, Fausto, Wu, Xifeng, Rashid, Asif, Pattabiraman, Nagarajan, Mazumder, Raja, Horvath, Anelia, Wu, Ray-Chang, Li, Shulin, Xiao, Cuiying, Deng, Chu-Xia, Wheeler, David A., Mishra, Bibhuti, Akbani, Rehan, and Mishra, Lopa

Published
2018
Full Text
View/download PDF

13. β-CATENIN stabilizes HIF2 through lncRNA and inhibits intravenous immunoglobulin immunotherapy

Author

Nakagawa, Chad, primary, Kadlera Nagaraj, Manjunatha, additional, Hernandez, Juan Carlos, additional, Uthay Kumar, Dinesh Babu, additional, Shukla, Vivek, additional, Machida, Risa, additional, Schüttrumpf, Jörg, additional, Sher, Linda, additional, Farci, Patrizia, additional, Mishra, Lopa, additional, Tahara, Stanley M., additional, Ou, Jing-Hsiung James, additional, and Machida, Keigo, additional

Published
2023
Full Text
View/download PDF

20. Figure S3 from Molecular Signature and Mechanisms of Hepatitis D Virus–Associated Hepatocellular Carcinoma

Author

Diaz, Giacomo, primary, Engle, Ronald E., primary, Tice, Ashley, primary, Melis, Marta, primary, Montenegro, Stephanie, primary, Rodriguez-Canales, Jaime, primary, Hanson, Jeffrey, primary, Emmert-Buck, Michael R., primary, Bock, Kevin W., primary, Moore, Ian N., primary, Zamboni, Fausto, primary, Govindarajan, Sugantha, primary, Kleiner, David E., primary, and Farci, Patrizia, primary

Published
2023
Full Text
View/download PDF

21. Data from Molecular Signature and Mechanisms of Hepatitis D Virus–Associated Hepatocellular Carcinoma

Author

Diaz, Giacomo, primary, Engle, Ronald E., primary, Tice, Ashley, primary, Melis, Marta, primary, Montenegro, Stephanie, primary, Rodriguez-Canales, Jaime, primary, Hanson, Jeffrey, primary, Emmert-Buck, Michael R., primary, Bock, Kevin W., primary, Moore, Ian N., primary, Zamboni, Fausto, primary, Govindarajan, Sugantha, primary, Kleiner, David E., primary, and Farci, Patrizia, primary

Published
2023
Full Text
View/download PDF

22. Hepatitis E prevalence and infection in solid‐organ transplant recipients in the United States

Author

Samala, Niharika, primary, Wang, Richard Y., additional, Auh, Sungyoung, additional, Balla, Abdalla Kara, additional, Dakhoul, Lara, additional, Alter, Harvey J., additional, Farci, Patrizia, additional, Ghabril, Marwan, additional, Lucey, Michael R., additional, Rangnekar, Amol S., additional, Reddy, K. Rajender, additional, and Ghany, Marc G., additional

Published
2022
Full Text
View/download PDF

25. Loss of the transforming growth factor‐β effector β2‐Spectrin promotes genomic instability

Author

Chen, Jian, Shukla, Vivek, Farci, Patrizia, Andricovich, Jaclyn, Jogunoori, Wilma, Kwong, Lawrence N., Katz, Lior H., Shetty, Kirti, Rashid, Asif, Su, Xiaoping, White, Jon, Li, Lei, Wang, Alan Yaoqi, Blechacz, Boris, Raju, Gottumukkala S., Davila, Marta, Nguyen, Bao‐Ngoc, Stroehlein, John R., Chen, Junjie, Kim, Sang Soo, Levin, Heather, Machida, Keigo, Tsukamoto, Hidekazu, Michaely, Peter, Tzatsos, Alexandros, Mishra, Bibhuti, Amdur, Richard, and Mishra, Lopa

Published
2017
Full Text
View/download PDF

32. Transfusion-associated Hepatitis (TAH) in Polytransfused Thalassemic Children Following the Introduction of Anti-HCV Donor Screening in Sardinia

Author

Lai, Maria Eliana, Argiolu, Francesca, Farci, Patrizia, Lisci, Vitalia, Mazzoleni, Anna Paola, Dessi, Carlo, Coiana, Alessandra, Tronci, Maria B., De Virgilis, Stefano, Arnone, Michele, Balestrieri, Angelo, Cao, Antonio, Nishioka, K., editor, Suzuki, H., editor, Mishiro, S., editor, and Oda, T., editor

Published
1994
Full Text
View/download PDF

35. Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants

Author

Chen, Zhaochun, primary, Zhang, Peng, additional, Matsuoka, Yumiko, additional, Tsybovsky, Yaroslav, additional, West, Kamille, additional, Santos, Celia, additional, Boyd, Lisa F., additional, Nguyen, Hanh, additional, Pomerenke, Anna, additional, Stephens, Tyler, additional, Olia, Adam S., additional, De Giorgi, Valeria, additional, Holbrook, Michael R., additional, Gross, Robin, additional, Postnikova, Elena, additional, Garza, Nicole L., additional, Johnson, Reed F., additional, Margulies, David H., additional, Kwong, Peter D., additional, Alter, Harvey J., additional, Buchholz, Ursula J., additional, Lusso, Paolo, additional, and Farci, Patrizia, additional

Published
2022
Full Text
View/download PDF

37. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

Author

Lampertico, Pietro, Viganò, Mauro, Di Costanzo, Giovan Giuseppe, Sagnelli, Evangelista, Fasano, Massimo, Di Marco, Vito, Boninsegna, Sara, Farci, Patrizia, Fargion, Silvia, Giuberti, Tiziana, Iannacone, Claudio, Regep, Loredana, Massetto, Benedetta, Facchetti, Floriana, Colombo, Massimo, Andreone, Pietro, Riili, Anna, Scuteri, Alessandra, Cursaro, Carmela, Andriulli, Angelo, Anna Niro, Grazia, Angarano, Gioacchino, Fasano, Massimo, Santantonio, Teresa Antonia, Palattella, Maria Stefania, Brunetto, Maurizia, Colombatto, Piero, Coco, Barbara, Ciccorossi, Pietro, Oliveri, Filippo, Sacco, Rodolfo, Bruno, Savino, Bollani, Simona, Chiesa, Alberto, Carosi, Giampiero, Baiguera, Chiara, Rossi, Stefania, Zaltron, Serena, Puoti, Massimo, Colombo, Massimo, Lampertico, Pietro, Cozzolongo, Raffaele, Giannuzzi, Vito, Craxì, Antonio, Di Marco, Vito, Calvaruso, Vincenza, Venezia, Giovanna, Di Costanzo, Giovan Giuseppe, Lanza, Alfonso Galeota, Di Perri, Giovanni, Cariti, Giuseppe, Mollaretti, Oscar, De Blasi, Tiziano, Kulmiye, Cumar, Rostagno, Roberto, Farci, Patrizia, Eliana Lai, Maria, Serra, Giancarlo, Chessa, Luchino, Balestrieri, Cinzia, Cauli, Cristiana, Fargion, Silvia Rossana, Bertelli, Cristina, Fatta, Erika, Fattovich, Giovanna, Pasino, Michela, Zanni, Silvia, Olivari, Nicola, Zagni, Irene, Ferrari, Carlo, Schivazappa, Simona, Giuberti, Tiziana, Laccabue, Diletta, Penna, Amalia, Gaeta, Giovanbattista, Stanzione, Maria, Stornaiuolo, Gianfranca, Martines, Diego, Boninsegna, Sara, Raimondo, Giovanni, Caccamo, Gaia, Squadrito, Giovanni, Isgrò, Graziella, Rizzetto, Mario, Lagget, Marco, Carenzi, Silvia, Ruggiero, Giuseppe, Marrone, Aldo, Sagnelli, Evangelista, Messina, Vincenzo, Ulisse Di Caprio, Domenico Umberto, Selva, Vincenzo, and Toniutto, Pierluigi

Published
2013
Full Text
View/download PDF

42. Anti-PF4 antibodies associated with disease severity in COVID-19.

Author

Qingbo Liu, Huiyi Miao, Shuai Li, Peng Zhang, Gerber, Gloria F., Follmann, Dean, Hongkai Ji, Zeger, Scott L., Chertow, Daniel S., Quinn, Thomas C., Robinson, Matthew L., Kickler, Thomas S., Rothman, Richard E., Fenstermacher, Katherine Z. J., Braunstein, Evan M., Cox, Andrea L., Farci, Patrizia, Fauci, Anthony S., and Lusso, Paolo

Subjects
HOSPITAL patients, COVID-19, PATIENTS, COVID-19 pandemic, IMMUNOGLOBULINS, AUTOPSY
Abstract

Severe COVID-19 is characterized by a prothrombotic state associated with thrombocytopenia, with microvascular thrombosis being almost invariably present in the lung and other organs at postmortem examination. We evaluated the presence of antibodies to platelet factor 4 (PF4)–polyanion complexes using a clinically validated immunoassay in 100 hospitalized patients with COVID-19 with moderate or severe disease (World Health Organization score, 4 to 10), 25 patients with acute COVID-19 visiting the emergency department, and 65 convalescent individuals. Anti-PF4 antibodies were detected in 95 of 100 hospitalized patients with COVID-19 (95.0%) irrespective of prior heparin treatment, with a mean optical density value of 0.871 ± 0.405 SD (range, 0.177 to 2.706). In contrast, patients hospitalized for severe acute respiratory disease unrelated to COVID-19 had markedly lower levels of the antibodies. In a high proportion of patients with COVID-19, levels of all three immunoglobulin (Ig) isotypes tested (IgG, IgM, and IgA) were simultaneously elevated. Antibody levels were higher in male than in female patients and higher in African Americans and Hispanics than in White patients. Anti-PF4 antibody levels were correlated with the maximum disease severity score and with significant reductions in circulating platelet counts during hospitalization. In individuals convalescent from COVID-19, the antibody levels returned to near-normal values. Sera from patients with COVID-19 induced higher levels of platelet activation than did sera from healthy blood donors, but the results were not correlated with the levels of anti-PF4 antibodies. These results demonstrate that the vast majority of patients with severe COVID-19 develop anti-PF4 antibodies, which may play a role in the clinical complications of COVID-19. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

Author

Marcellin, Patrick, Farci, Patrizia, Lu, Zhi-Meng, Yurdaydin, Cihan, Lai, Ming-Yang, Pluck, Nigel, Button, Peter, Gurel, Selim, Diago, Moises, Germanidis, Georgios, Piratvisuth, Teerha, Jin, Rui, Hadziyannis, Stephanos, Bonino, Ferruccio, and Lau, George K.K.

Subjects
Lamivudine -- Research, Liver failure -- Causes of, Chronic active hepatitis -- Risk factors
Abstract

Chronic Hepatitis B is associated with serious complications including liver failure, cirrhosis and hepatocellular carcinoma. Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results